Cost Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared to Monotherapy for Metastatic Melanoma from a US Societal Perspective
May 1, 2016, 00:00
10.1016/j.jval.2016.03.502
https://www.valueinhealthjournal.com/article/S1098-3015(16)00570-2/fulltext
Title :
Cost Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared to Monotherapy for Metastatic Melanoma from a US Societal Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00570-2&doi=10.1016/j.jval.2016.03.502
First page :
A124
Section Title :
Sensory System Disorders - Cost Studies
Open access? :
No
Section Order :
159